Spyre Therapeutics priced an underwritten public offering of 6.5 million shares at $62.00 per share, generating approximately $403 million in gross proceeds. The offering is expected to close on April 16, 2026. Joint book-running managers include Jefferies LLC, Goldman Sachs & Co. LLC, Evercore ISI, and Guggenheim Securities, LLC.

Spyre Therapeutics, a clinical-stage biotechnology company focused on inflammatory bowel disease treatments, announced a proposed underwritten public offering of $300 million in common stock, with an additional $45 million option for underwriters. The offering is subject to market conditions and regulatory approval, with Jefferies LLC, Goldman Sachs & Co. LLC, Evercore ISI, and Guggenheim Securities serving as joint book-running managers.

Spyre Therapeutics, a clinical-stage biotechnology company focused on IBD and immune-mediated diseases, announced a $300 million underwritten public offering of common stock with a potential additional $45 million option for underwriters. The offering is led by Jefferies LLC, Goldman Sachs & Co. LLC, Evercore ISI, and Guggenheim Securities as joint book-running managers.

Spyre Therapeutics announced positive Phase 2 SKYLINE trial results for SPY001, an extended half-life anti-α4β7 antibody for moderate-to-severe ulcerative colitis. SPY001 met its primary endpoint with a statistically significant 9.2-point reduction in Robart's Histopathology Index score (p<0.0001) at Week 12, with secondary endpoints showing 40% clinical remission and 51% endoscopic improvement rates. The drug demonstrated a favorable safety profile consistent with its class. Part A enrollment has closed and Part B is now enrolling monotherapy and combination cohorts.

VR Adviser, LLC increased its position in Spyre Therapeutics by 1 million shares (estimated $25.78 million) in Q4, bringing total holdings to 3.68 million shares valued at $120.74 million (5.96% of AUM). Spyre Therapeutics, a preclinical-stage biotech company developing antibody therapies for inflammatory bowel disease, has seen its stock surge 132.1% over the past year. The article cautions that while VR Adviser is specialist biotech fund with deep expertise, Spyre's preclinical status and binary pipeline risk make it unsuitable for most individual investors.

Commodore Capital increased its stake in Spyre Therapeutics by 400,161 shares ($10.46 million) in Q4, bringing its total position to $78.24 million (5.21% of AUM). SYRE stock has surged 63% over the past year, significantly outperforming the S&P 500's 13% gain. The preclinical biotech company, focused on inflammatory bowel disease treatments, has a strong balance sheet with $757 million in cash and expects runway into H2 2028, with six Phase 2 readouts expected in 2026.

Spyre Therapeutics announced the appointment of Kate Chevlen as Chief Commercial Officer, granting her 108,155 stock options at an exercise price of $34.09 per share as an inducement award. The options vest over four years with a 10-year term.

Spyre Therapeutics CEO Cameron Turtle sold 15,000 shares for approximately $460,000 on January 2, 2026, representing 2.2% of his direct holdings. The sale was conducted under a prearranged 10b5-1 trading plan, which is a standard practice for insiders to avoid appearance of impropriety. After the transaction, Turtle retained approximately 671,907 shares valued at $20.5 million. The analyst notes the sale is not concerning given the scheduled nature of the plan.

Spyre Therapeutics presented scientific data on SPY072, a potential first-in-class anti-TL1A agent for rheumatic diseases, showcasing promising Phase 1 study results with potential quarterly or twice-yearly dosing and preclinical efficacy comparable to etanercept.

Spyre Therapeutics plans to raise approximately $275 million through a public offering of 14,864,865 common stock shares at $18.50 per share, with potential additional shares through underwriter options.

Spyre Therapeutics presented interim Phase 1 results for SPY002, an anti-TL1A antibody for IBD, showing promising dosing potential and preclinical data supporting combination therapy efficacy.

Spyre Therapeutics granted stock options to five non-executive employees under its 2018 Equity Inducement Plan, with options vesting over four years and an exercise price of $16.26 per share.